Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Sung-Koo Kang  (Kang SK) 3 Articles
Clinical Study
Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Bo-Yeon Kim
Endocrinol Metab. 2018;33(3):387-394.   Published online September 18, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.387
  • 5,531 View
  • 117 Download
  • 36 Web of Science
  • 35 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with non-alcoholic fatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study was designed to investigate the effect of dapagliflozin, one of the SGLT2i, on the liver function of T2DM with NAFLD when combined with metformin.

Methods

Among patients who received dual oral hypoglycemic agents within the 3 months of diagnosing NAFLD, patients who had abnormal alanine aminotransferase (ALT) level (>40 IU/L) were included. Patients were divided into two groups: metformin+dapagliflozin group and metformin+dipeptidyl peptidase-4 inhibitors (DPP4i) group. Demographic data, biochemical data and the clinical and treatment histories of all patients were reviewed.

Results

A total of 102 patients were included (dapagliflozin group, n=50; DPP4i group, n=52). Dapagliflozin group showed more weight loss and more ALT decline than DPP4i group (−2.9 kg vs. −0.4 kg, P=0.005; −21.1 U/L vs. −9.5 U/L, P=0.008, respectively) and the proportion of patients with ALT normalization after treatment was also significantly higher in the dapagliflozin group (80.0% vs. 61.5%, P=0.041). The effect of dapagliflozin with metformin on ALT normalization remained significant after adjustment for confounding variables including body weight loss (odds ratio, 3.489; P=0.046).

Conclusion

ALT improvement was statistically significant in the dapagliflozin than the DPP4i when combined with metformin and the result was consistent after adjustment for confounding variables including body weight loss.

Citations

Citations to this article as recorded by  
  • The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
    Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi, Theodoros Androutsakos
    European Journal of Clinical Pharmacology.2024; 80(1): 127.     CrossRef
  • Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
    Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, Takumi Lee, Mitsuhiro Rokuda
    Diabetes, Obesity and Metabolism.2024; 26(3): 997.     CrossRef
  • Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
    Vicente Pallarés-Carratalá, Antonio Ruiz-García, Adalberto Serrano-Cumplido, Antonio Segura Fragoso, Verónica Fernández-Pascual, Beatriz Sánchez-Sánchez, María Inmaculada Cervera-Pérez, Francisco Javier Alonso-Moreno, Ezequiel Arranz-Martínez, Alfonso Bar
    Clínica e Investigación en Arteriosclerosis.2024;[Epub]     CrossRef
  • Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
    Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso
    Biomedicines.2023; 11(2): 322.     CrossRef
  • Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet
    Yong Zhang, Jie Xu, Di Zhou, Tingting Ye, Puqing Zhou, Zuofeng Liu, Xinyuan Liu, Zinan Wang, Tianmiao Hua, Zhenghao Zhang, Qingyan Sun
    Molecular Medicine.2023;[Epub]     CrossRef
  • Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review
    Agnieszka Polecka, Natalia Olszewska, Łukasz Danielski, Ewa Olszewska
    Journal of Clinical Medicine.2023; 12(19): 6139.     CrossRef
  • Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
    Iryna Kostitska, Nadia Protas, Liliia Petrovska
    Diabetes Obesity Metabolic Syndrome.2023; (5): 8.     CrossRef
  • Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
    Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
    International Journal of Diabetes in Developing Countries.2022; 42(2): 290.     CrossRef
  • The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
    Manqiu Mo, Zichun Huang, Yuzhen Liang, Yunhua Liao, Ning Xia
    Digestive and Liver Disease.2022; 54(4): 461.     CrossRef
  • Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
    Reem M. Hazem, Ahmed Z. Ibrahim, Dina A. Ali, Yasser M. Moustafa
    International Immunopharmacology.2022; 104: 108503.     CrossRef
  • SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
    Theodoros Androutsakos, Narjes Nasiri-Ansari, Athanasios-Dimitrios Bakasis, Ioannis Kyrou, Efstathios Efstathopoulos, Harpal S. Randeva, Eva Kassi
    International Journal of Molecular Sciences.2022; 23(6): 3107.     CrossRef
  • Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
    Panshuang Qiao, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
    Yumie Takeshita, Masao Honda, Kenichi Harada, Yuki Kita, Noboru Takata, Hiromasa Tsujiguchi, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
    Diabetes Care.2022; 45(9): 2064.     CrossRef
  • Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
    Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, Felice Strollo
    Advances in Therapy.2022; 39(11): 4837.     CrossRef
  • Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms
    Hager H. Shaaban, Ibrahim Alzaim, Ahmed El-Mallah, Rania G. Aly, Ahmed F. El-Yazbi, Ahmed Wahid
    Life Sciences.2022; 308: 120956.     CrossRef
  • The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
    Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, Evangelos Cholongitas
    Journal of Gastroenterology and Hepatology.2021; 36(4): 893.     CrossRef
  • Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
    Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, Yip Han Chin, Yi Fen Low, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
    Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho, Adelino Leite‐Moreira
    Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
  • Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
    Elizabeth M. Lamos, Megan Kristan, Maka Siamashvili, Stephen N. Davis
    Expert Review of Clinical Pharmacology.2021; 14(7): 837.     CrossRef
  • Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Won Euh, Soo Lim, Jin-Wook Kim
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway
    Jingyi Luo, Pengbo Sun, Yangyang Wang, Yang Chen, Yaoyun Niu, Yipei Ding, Naihan Xu, Yaou Zhang, Weidong Xie
    European Journal of Pharmacology.2021; 907: 174304.     CrossRef
  • The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
    Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit, Apinya Leerapun, Arintaya Phrommintikul, Supawan Buranapin, Nipon Chattipakorn, Satawat Thongsawat
    Journal of Gastroenterology and Hepatology.2021; 36(10): 2952.     CrossRef
  • Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
    Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile
    Advances in Therapy.2021; 38(8): 4195.     CrossRef
  • Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B
    Lilian Yan Liang, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Grace Chung‐Yan Lui, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong
    GastroHep.2021; 3(4): 261.     CrossRef
  • Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
    Kanokwan Pinyopornpanish, Apinya Leerapun, Kanokporn Pinyopornpanish, Nipon Chattipakorn
    Gut and Liver.2021; 15(6): 827.     CrossRef
  • The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
    F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, Randall L. Halcomb
    Journal of Medicinal Chemistry.2020; 63(10): 5031.     CrossRef
  • SGLT2 Inhibitors in Liver Patients
    John Chen Hsiang, Vincent Wai-Sun Wong
    Clinical Gastroenterology and Hepatology.2020; 18(10): 2168.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2019; 92: 82.     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
    Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
    Diabetes & Metabolism Journal.2019; 43(2): 127.     CrossRef
  • Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet
    Fan Zheng, Ying Cai
    Lipids in Health and Disease.2019;[Epub]     CrossRef
  • The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
    Chan-Hee Jung, Ji-Oh Mok
    Journal of Obesity & Metabolic Syndrome.2019; 28(1): 18.     CrossRef
  • Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
    Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
    Metabolism.2019; 98: iii.     CrossRef
  • Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
    Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
    Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef
  • Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
    A.J. Scheen
    Diabetes & Metabolism.2019; 45(3): 213.     CrossRef
Close layer
Obesity and Metabolism
Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance
Kyu-Jin Kim, Bo-Yeon Kim, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Chan-Hee Jung
Endocrinol Metab. 2015;30(3):318-325.   Published online May 18, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.3.318
  • 4,184 View
  • 45 Download
  • 10 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   
Background

Thyroid hormones can influence energy metabolism and insulin sensitivity via their interaction with adipocytokines and gut hormones. The aims of this study were to evaluate differences in serum ghrelin and leptin concentrations according to thyroid hormone levels, and to investigate the correlation of insulin resistance.

Methods

A total of 154 patients (57 hyperthyroid patients, 61 euthyroid patients, and 36 hypothyroid patients; mean age, 47.9 years) were enrolled. Serum leptin, ghrelin, and insulin levels were measured and insulin resistance was calculated using the formula of the homeostasis model assessment of insulin resistance (HOMA-IR).

Results

There were no differences in mean concentrations of ghrelin or leptin among the three groups. There were no significant differences in insulin levels between the groups (P=0.06), although hyperthyroid patients had borderline statistically significantly higher levels of insulin than did euthyroid subjects by post hoc test (26.4 µIU/mL vs. 16.1 µIU/mL, P=0.057). Regarding HOMA-IR index, the mean levels were highest in the hyperthyroid group among those of the three groups (hyperthyroid vs. euthyroid vs. hypothyroid, 6.7 vs. 3.8 vs. 4.4, P=0.068). Plasma levels of ghrelin were significantly negatively correlated with age, insulin, glucose, body mass index (BMI), and HOMA-IR. Plasma levels of leptin showed significant positive correlation with BMI and triglyceride. There were no significant correlations among thyroid hormone, thyrotropin, ghrelin, leptin, or insulin.

Conclusion

The present study found that serum ghrelin, leptin, and insulin levels didn't differ according to thyroid function conditions. Further studies with larger numbers of patients are required to establish a direct relationship between plasma ghrelin, leptin, and thyroid hormone.

Citations

Citations to this article as recorded by  
  • Thyroid disorders and gastrointestinal dysmotility: an old association
    Guang-Meng Xu, Ming-Xin Hu, Si-Yu Li, Xuan Ran, Hao Zhang, Xiang-Fu Ding
    Frontiers in Physiology.2024;[Epub]     CrossRef
  • Insulin resistance, leptin and adiponectin in lean and hypothyroid children and adolescents with obesity
    Doaa El Amrousy, Dalia El-Afify, Shaimaa Salah
    BMC Pediatrics.2022;[Epub]     CrossRef
  • Mediators of energy homeostasis in hyperthyroidism
    Avinash Patil, Suresh Vaikkakara, Mani Deepthi Dasari, Sandeep Ganta, Alok Sachan, Kiranmayi S. Vinapamula
    Archives of Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • STUDY OF GHRELIN LEVELS IN HYPOTHYROID PATIENTS BEFORE AND AFTER TREATMENT
    Peeyush Yadav, G. G. Kaushik
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 52.     CrossRef
  • Acylated Ghrelin Attenuates l-Thyroxin–induced Cardiac Damage in Rats by Antioxidant and Anti-inflammatory Effects and Downregulating Components of the Cardiac Renin–angiotensin System
    Rehab Badi
    Journal of Cardiovascular Pharmacology.2021; 78(3): 422.     CrossRef
  • Experimental hypothyroidism in adult male rats: the effects of Artemisia dracunculus aqueous extract on serum thyroid hormones, lipid profile, leptin, adiponectin, and antioxidant factors
    Mohammad Mohsen Mohammadi, Mahdi Saeb, Saeed Nazifi
    Comparative Clinical Pathology.2020; 29(2): 485.     CrossRef
  • Leptin, neuropeptide Y (NPY), melatonin and zinc levels in experimental hypothyroidism and hyperthyroidism: relation with melatonin and the pineal gland
    Abdulkerim Kasım Baltaci, Rasim Mogulkoc
    Hormone Molecular Biology and Clinical Investigation.2018;[Epub]     CrossRef
  • Leptin, NPY, Melatonin and Zinc Levels in Experimental Hypothyroidism and Hyperthyroidism: The Relation to Zinc
    Abdulkerim Kasım Baltaci, Rasim Mogulkoc
    Biochemical Genetics.2017; 55(3): 223.     CrossRef
  • Thyroid Hormone Regulation and Insulin Resistance: Insights From Animals Naturally Adapted to Fasting
    Bridget Martinez, Rudy M. Ortiz
    Physiology.2017; 32(2): 141.     CrossRef
  • Role of the Orexin System on the Hypothalamus-Pituitary-Thyroid Axis
    Antonietta Messina, Carolina De Fusco, Vincenzo Monda, Maria Esposito, Fiorenzo Moscatelli, Anna Valenzano, Marco Carotenuto, Emanuela Viggiano, Sergio Chieffi, Vincenzo De Luca, Giuseppe Cibelli, Marcellino Monda, Giovanni Messina
    Frontiers in Neural Circuits.2016;[Epub]     CrossRef
  • Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance (Endocrinol Metab2015;30:318-25, Kyu-Jin Kim et al.)
    Jin Hwa Kim
    Endocrinology and Metabolism.2015; 30(4): 631.     CrossRef
  • Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance (Endocrinol Metab2015;30:318-25, Kyu-Jin Kim et al.)
    Chan-Hee Jung
    Endocrinology and Metabolism.2015; 30(4): 633.     CrossRef
Close layer
Obesity and Metabolism
Association between Cardiac Autonomic Neuropathy, Diabetic Retinopathy and Carotid Atherosclerosis in Patients with Type 2 Diabetes
Chan-Hee Jung, Ae-Rin Baek, Kyu-Jin Kim, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
Endocrinol Metab. 2013;28(4):309-319.   Published online December 12, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.4.309
  • 4,578 View
  • 38 Download
  • 22 Crossref
AbstractAbstract PDFPubReader   
Background

It is not clear whether microangiopathies are associated with subclinical atherosclerosis in type 2 diabetes mellitus (T2DM). We investigated the relation of cardiac autonomic neuropathy (CAN) and other microangiopathies with carotid atherosclerosis in T2DM.

Methods

A total of 131 patients with T2DM were stratified by mean carotid intima-media thickness (CIMT) ≥ or <1.0 mm and the number of carotid plaques. CAN was assessed by the five standard cardiovascular reflex tests according to the Ewing's protocol. CAN was defined as the presence of at least two abnormal tests or an autonomic neuropathy points ≥2. Diabetic microangiopathies were assessed.

Results

Patients with CAN comprised 77% of the group with mean CIMT ≥1.0 mm, while they were 29% of the group with CIMT <1.0 mm (P=0.016). Patients with diabetic retinopathy (DR) comprised 68% of the group with CIMT ≥1.0 mm, while they were 28% of the group without CIMT thickening (P=0.003). Patients with CAN comprised 51% of the group with ≥2 carotid plaques, while they were 23% of the group with ≤1 carotid plaque (P=0.014). In multivariable adjusted logistic regression analysis, the patients who presented with CAN showed an odds ratio [OR] of 8.6 (95% confidence interval [CI], 1.6 to 44.8) for CIMT thickening and an OR of 2.9 (95% CI, 1.1 to 7.5) for carotid plaques. Furthermore, patients with DR were 3.8 times (95% CI, 1.4 to 10.2) more likely to have CIMT thickening.

Conclusion

These results suggest that CAN is associated with carotid atherosclerosis, represented as CIMT and plaques, independent of the traditional cardiovascular risk factors in T2DM. CAN or DR may be a determinant of subclinical atherosclerosis in T2DM.

Citations

Citations to this article as recorded by  
  • Common carotid artery intima media thickness (CIMT) in patients with prediabetes and newly diagnosed type 2 diabetes mellitus
    Antoaneta Gateva, Yavor Assyov, Vera Karamfilova, Zdravko Kamenov
    Journal of Diabetes and its Complications.2024; 38(7): 108766.     CrossRef
  • Carotid atherosclerosis: An independent risk factor for small fiber nerve dysfunction in patients with type 2 diabetes mellitus
    Simin Guo, Yali Jing, Chenxi Li, Dalong Zhu, Weimin Wang
    Journal of Diabetes Investigation.2023; 14(2): 289.     CrossRef
  • Evaluating Diagnostic Ultrasound of the Vagus Nerve as a Surrogate Marker for Autonomic Neuropathy in Diabetic Patients
    Bianka Heiling, Adriana Karl, Nadin Fedtke, Nicolle Müller, Christof Kloos, Alexander Grimm, Hubertus Axer
    Medicina.2023; 59(3): 525.     CrossRef
  • Albuminuria but not low eGFR is closely associated with atherosclerosis in patients with type 2 diabetes: an observational study
    Jun-Wei Wang, Jiang-Feng Ke, Zhi-Hui Zhang, Jun-Xi Lu, Lian-Xi Li
    Diabetology & Metabolic Syndrome.2022;[Epub]     CrossRef
  • Predictive Value of the Advanced Lipoprotein Profile and Glycated Proteins on Diabetic Retinopathy
    Josep Julve, Joana Rossell, Eudald Correig, Marina Idalia Rojo-Lopez, Nuria Amigó, Marta Hernández, Alicia Traveset, Marc Carbonell, Nuria Alonso, Didac Mauricio, Esmeralda Castelblanco
    Nutrients.2022; 14(19): 3932.     CrossRef
  • The relationship between carotid disease and retinopathy in diabetes: a systematic review
    Jocelyn J. Drinkwater, Timothy M. E. Davis, Wendy A. Davis
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II
    Jocelyn J. Drinkwater, Fred K. Chen, Alison M. Brooks, Brad T. Davis, Angus W. Turner, Timothy M.E. Davis, Wendy A. Davis
    Diabetes Care.2020; 43(12): 3034.     CrossRef
  • Diabetic foot – invalidating complication of diabetes mellitus
    Oana Manuela Spălăţelu, Sergiu Chirila, Leonard Gurgas, Vasile Sârbu
    Medic.ro.2019; 3(129): 40.     CrossRef
  • Clinical factors associated with the recovery of cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus
    Ji Eun Jun, Seung-Eun Lee, Min Sun Choi, Sung Woon Park, You-Cheol Hwang, Jae Hyeon Kim
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Association of carotid intima-media thickness with exercise tolerance test in type 2 diabetic patients
    Ali Momeni, Abdolmajid Taheri, Maryam Mansuri, Ali Bazdar, Morteza Sedehi, Masoud Amiri
    IJC Heart & Vasculature.2018; 21: 74.     CrossRef
  • Cardiac autonomic neuropathy may play a role in pathogenesis of atherosclerosis in type 1 diabetes mellitus
    Sarka Mala, Veronika Potockova, Lucie Hoskovcova, Pavlina Pithova, Marek Brabec, Jaroslava Kulhankova, Radan Keil, Lucie Riedlbauchova, Jan Broz
    Diabetes Research and Clinical Practice.2017; 134: 139.     CrossRef
  • Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes
    Akihiko Ando, Michiaki Miyamoto, Kazuhiko Kotani, Kenta Okada, Shoichiro Nagasaka, Shun Ishibashi
    Journal of Diabetes Research.2017; 2017: 1.     CrossRef
  • Cardiac Involvement in Peripheral Neuropathies
    Ahmet Z. Burakgazi, Soufian AlMahameed
    Journal of Clinical Neuromuscular Disease.2016; 17(3): 120.     CrossRef
  • The relationship between vitamin D status and cardiac autonomic neuropathy in patients with type 2 diabetes mellitus
    Chan-Hee Jung, Sang-Hee Jung, Kyu-Jin Kim, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
    Diabetes and Vascular Disease Research.2015; 12(5): 342.     CrossRef
  • Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes
    Na Fang, Wei Han, Dandan Gong, Zou Chen, Yu Fan
    Medicine.2015; 94(44): e1920.     CrossRef
  • Cardiovascular complications in patients with autonomic failure
    Valeria Milazzo, Cristina Di Stefano, Alberto Milan, Agnese Ravera, Gabriele Sobrero, Luca Sabia, Franco Veglio, Simona Maule
    Clinical Autonomic Research.2015; 25(3): 133.     CrossRef
  • Association of heart rate with albuminuria in a general adult population: the 2011 Korea National Health and Nutrition Examination Survey
    H. S. Choi, J. W. Hong, J. H. Lee, J. H. Noh, D. J. Kim
    Internal Medicine Journal.2015; 45(4): 428.     CrossRef
  • Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy
    Núria Alonso, Alicia Traveset, Esther Rubinat, Emilio Ortega, Nuria Alcubierre, Jordi Sanahuja, Marta Hernández, Angels Betriu, Carmen Jurjo, Elvira Fernández, Didac Mauricio
    Cardiovascular Diabetology.2015;[Epub]     CrossRef
  • Letter: Association between Cardiac Autonomic Neuropathy, Diabetic Retinopathy and Carotid Atherosclerosis in Patients with Type 2 Diabetes (Endocrinol Metab 2013;28:309-19, Chan-Hee Jung et al.)
    Hyun-Kyung Chung
    Endocrinology and Metabolism.2014; 29(1): 101.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
  • Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment
    M.K. Kim, K.-J. Yun, H.J. Chun, E.-H. Jang, K.-D. Han, Y.-M. Park, K.-H. Baek, K.-H. Song, B.-Y. Cha, C.S. Park, H.-S. Kwon
    Diabetes & Metabolism.2014; 40(6): 459.     CrossRef
  • Association between Brachial-Ankle pulse wave velocity and cardiac autonomic neuropathy in type 2 diabetes
    Nan Wu, Xiaoling Cai, Kuanping Ye, Yintao Li, Min He, Weiwei Zhao, Renming Hu
    Diabetology & Metabolic Syndrome.2014;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism